Gastrinoma clinical trials

The registry lists 35 studies for Gastrinoma across more than 10 countries. 0 are recruiting or about to start. 12 of them are mainly about Gastrinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-29.

Status

Completed: 23
Terminated: 7
Withdrawn: 3
Active, not recruiting: 1
Status unknown: 1

Phase

Phase 2: 22
Phase 1: 7
Phase 3: 3

Where

United States: 28
United Kingdom: 2
Canada: 2
Denmark: 1
Israel: 1
Germany: 1

Who runs them

National Cancer Institute (NCI) (6) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Novartis Pharmaceuticals (2) · Memorial Sloan Kettering Cancer Center (2) · Yale University (2) · ECOG-ACRIN Cancer Research Group (2) · Eastern Cooperative Oncology Group (2) · British Columbia Cancer Agency (2)

What is being tested here

Drugs under test in Gastrinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Phase 3	All
Temozolomide	0	3
Everolimus	0	3
Capecitabine	0	3
Vatalanib	0	2
Bevacizumab	1	2
Octreotide	0	2
Motesanib diphosphate	0	1
Regorafenib	0	1
Pantoprazole	0	1
Omeprazole	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 7 · Antimetabolites 5

Who these studies take

No Gastrinoma study is recruiting now.

Across all 35 studies, recruiting or not: 3% stop at 75 or younger and 3% at 65; 11% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 35 of 35. search them.